Daptomycin is a drug owned by Xellia Pharmaceuticals Aps. It is protected by 2 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 28, 2038. Details of Daptomycin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11759497 | Daptomycin formulations |
Aug, 2038
(13 years from now) | Active |
| US12053502 | Daptomycin formulations |
Aug, 2038
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Daptomycin's patents.
Latest Legal Activities on Daptomycin's Patents
Given below is the list of recent legal activities going on the following patents of Daptomycin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 20 Sep, 2023 | US11759497 |
| Recordation of Patent eGrant | 19 Sep, 2023 | US11759497 |
| Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
| Recordation of Patent Grant Mailed Critical | 19 Sep, 2023 | US11759497 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Sep, 2023 | US11759497 |
| Mail Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
| Email Notification Critical | 01 Sep, 2023 | US11759497 |
| Issue Notification Mailed Critical | 30 Aug, 2023 | US11759497 |
| Dispatch to FDC | 09 Aug, 2023 | US11759497 |
| Application Is Considered Ready for Issue Critical | 09 Aug, 2023 | US11759497 |
US patents provide insights into the exclusivity only within the United States, but Daptomycin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Daptomycin's family patents as well as insights into ongoing legal events on those patents.
Daptomycin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Daptomycin's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 28, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Daptomycin Generic API suppliers:
Daptomycin is the generic name for the brand Daptomycin. 19 different companies have already filed for the generic of Daptomycin, with Dr Reddys having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Daptomycin's generic
Alternative Brands for Daptomycin
Daptomycin which is used for treating complicated skin and skin structure infections, S. aureus bloodstream infections, and right-sided infective endocarditis., has several other brand drugs using the same active ingredient (Daptomycin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Baxter Hlthcare Corp |
| ||
| Cubist Pharms Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Daptomycin, Daptomycin's active ingredient. Check the complete list of approved generic manufacturers for Daptomycin
About Daptomycin
Daptomycin is a drug owned by Xellia Pharmaceuticals Aps. It is used for treating complicated skin and skin structure infections, S. aureus bloodstream infections, and right-sided infective endocarditis. Daptomycin uses Daptomycin as an active ingredient. Daptomycin was launched by Xellia Pharms Aps in 2023.
Approval Date:
Daptomycin was approved by FDA for market use on 30 January, 2023.
Active Ingredient:
Daptomycin uses Daptomycin as the active ingredient. Check out other Drugs and Companies using Daptomycin ingredient
Treatment:
Daptomycin is used for treating complicated skin and skin structure infections, S. aureus bloodstream infections, and right-sided infective endocarditis.
Dosage:
Daptomycin is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/VIAL | POWDER | Prescription | INTRAVENOUS |
| 350MG/VIAL | POWDER | Prescription | INTRAVENOUS |
Daptomycin is a drug owned by Hospira Inc. It is protected by 2 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 11, 2033. Details of Daptomycin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10357535 | Daptomycin formulations and uses thereof |
Sep, 2033
(8 years from now) | Active |
| US9655946 | Daptomycin formulations and uses thereof |
Sep, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Daptomycin's patents.
Latest Legal Activities on Daptomycin's Patents
Given below is the list of recent legal activities going on the following patents of Daptomycin.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Email Notification Critical | 20 Sep, 2023 | US11759497 |
| Recordation of Patent eGrant | 19 Sep, 2023 | US11759497 |
| Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
| Recordation of Patent Grant Mailed Critical | 19 Sep, 2023 | US11759497 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Sep, 2023 | US11759497 |
| Mail Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
| Email Notification Critical | 01 Sep, 2023 | US11759497 |
| Issue Notification Mailed Critical | 30 Aug, 2023 | US11759497 |
| Dispatch to FDC | 09 Aug, 2023 | US11759497 |
| Application Is Considered Ready for Issue Critical | 09 Aug, 2023 | US11759497 |
US patents provide insights into the exclusivity only within the United States, but Daptomycin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Daptomycin's family patents as well as insights into ongoing legal events on those patents.
Daptomycin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Daptomycin's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 11, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Daptomycin Generic API suppliers:
Daptomycin is the generic name for the brand Daptomycin. 19 different companies have already filed for the generic of Daptomycin, with Dr Reddys having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Daptomycin's generic
Alternative Brands for Daptomycin
Daptomycin which is used for treating complicated skin and skin structure infections, S. aureus bloodstream infections, and right-sided infective endocarditis., has several other brand drugs using the same active ingredient (Daptomycin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Baxter Hlthcare Corp |
| ||
| Cubist Pharms Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Daptomycin, Daptomycin's active ingredient. Check the complete list of approved generic manufacturers for Daptomycin
About Daptomycin
Daptomycin is a drug owned by Hospira Inc. It is used for treating complicated skin and skin structure infections, S. aureus bloodstream infections, and right-sided infective endocarditis. Daptomycin uses Daptomycin as an active ingredient. Daptomycin was launched by Hospira in 2021.
Approval Date:
Daptomycin was approved by FDA for market use on 21 June, 2021.
Active Ingredient:
Daptomycin uses Daptomycin as the active ingredient. Check out other Drugs and Companies using Daptomycin ingredient
Treatment:
Daptomycin is used for treating complicated skin and skin structure infections, S. aureus bloodstream infections, and right-sided infective endocarditis.
Dosage:
Daptomycin is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 350MG/VIAL | POWDER | Prescription | INTRAVENOUS |
| 500MG/VIAL | POWDER | Prescription | INTRAVENOUS |